| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| テイコクファルマケア株式会社 | ||||||||
|
|
||||||||
|
|
||||||||
| Ota Pharmaceutical Co., Ltd. | ||||||||
| 帝國漢方製薬株式会社 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| Seren Pharma Co., Ltd. | ||||||||
|
|
||||||||
| 香川県製薬株式会社 |
The fifth-generation head, Akazawa Shozo, inherits a pharmaceutical trading stock and opens a business. Certificate of the 'pharmaceutical stock'.
Akazawa Chutaro obtains a license to open a pharmacy.
Obtains permission to sell 'Jousosan' (the beginning of our pesticide).
Establishes 'Teikoku Pharmaceutical Co., Ltd.' with a capital of 1 million yen. Company flag at the time of founding.
Launches the yellow phosphorus pesticide 'Yakune'. Signboard of 'Yakune'.
Launches 'Holkys®', the origin of the pouch agent.
Merges 212 companies under Kagawa Prefecture and establishes 'Kagawa Prefecture Pharmaceutical Co., Ltd.' as a controlling company, with Akazawa Chutaro as the first president.
Establishes Osaka factory in Higashiyodogawa-ku, Osaka City (now Yodogawa-ku).
Separates Osaka factory. Osaka factory is newly established as 'Fusō Chemical Industries Co., Ltd.' with Akazawa Shozo as president.
Obtains medical practitioner approval for the pouch agent, becoming the company's main product.
Completion of the first phase of the new pouch agent factory (old Factory 1) in 1978. Factory interior around 1975.
Completion of a 9-story formulation development research institute (now management building) on the headquarters site.
Establishes 'Teikoku Kampo Pharmaceutical Co., Ltd.' and completes its Hakata factory in Shirotori Town, Kagawa Prefecture (now Higashikagawa City Minato).
Acquires shares of Ota Pharmaceutical Co., Ltd. and participates in management.
Approval obtained and manufacturing commenced for Japan's first medical indometacin patch, 'KATRELP®'. A new 5-story factory covering 6,451 square meters (now the second factory) was completed on the company premises.
Delivery center completed in Shirotori Town, Kagawa Prefecture (now Minato, Higashikagawa City). Shirotori Distribution Center.
Established a donated lecture at Kagawa Medical University (now Kagawa University School of Medicine) titled 'Pharmacological Bioinformatics'.
Separated the sales division and established 'Teikoku Medics Co., Ltd.'.
Fourth factory (tape and ointment factory) completed. The Ikeda factory specializing in antiseptic agents began operation in Ikeda Town, Tokushima Prefecture (now Miyoshi City) (transferred to Ikeda Yakuso Co., Ltd. in 2014). Approval obtained and manufacturing commenced for the medical ferbinaq patch, 'CELTACH®'.
Tokushima Factory (Teikoku Kampo Pharmaceutical Co., Ltd.) operational
Separated the OTC (over-the-counter) division and established 'Teikoku Pharma Care Co., Ltd.' Joined the Japan Pharmaceutical Manufacturers Association.
Acquired the site of the former Toyo Bouseki Co., Ltd. Mihomomatsu factory adjacent to the headquarters. Established the U.S. subsidiary 'Teikoku Pharma USA, Inc.'. Acquired land next to the Tokushima factory and commenced operation of the Tosei factory specializing in cosmetics and related products.
Celebrated the 150th anniversary of founding and the 80th anniversary of company establishment. Published '150-Year History of Founding'. Issued a 150th-anniversary commemorative mark.
In the United States, the new drug approval and sales launch of the postherpetic neuralgia treatment patch 'Lidoderm®'.
Approval and sales launch of the psoriasis treatment ointment 'DOBONEX® Ointment' (transferred to Leo Pharma Co., Ltd. in 2014). Completed and commenced operation of the 8th factory on the Toyo Bouseki site. 8th factory.
Obtained approval and commenced manufacturing of morphine sulfate sustained-release capsules. 7th factory operational.
Established the joint venture company 'Fusō Teiyaku (Qingdao) Co., Ltd.' among Teikoku Pharmaceutical, Fusō Chemical Industry, and Qingdao Fusō Refining and Processing Co., Ltd. Completed the new drug research building.
Completed the new headquarters and factory of Teikoku Pharma USA, Inc. New headquarters of Teikoku Pharma USA, Inc.
Released Japan's first over-the-counter ketoprofen patch 'Omniid® Ketoprofen Patch' from Teikoku Pharma Care Co., Ltd. The Tokyo office relocated to its own building in Nihonbashi Motomachi. Completed a new drug research building on the Mihomomatsu factory site.
New drug research building.
Completed the Historical Museum, Akazawa Seiko Hall, and the guest house 'Twin Island'.
Celebrated the 160th anniversary of founding and the 90th anniversary of company establishment.
Sold Teikoku Medics Co., Ltd.
Completed a new warehouse adjacent to the Tokushima warehouse.
Obtained approval for the medical ferbinaq tape 'CELTACH® Tape 70' and commenced sales the following year.
Approval obtained and sales commenced for the medical indometacin tape formulations 'KATRELP® Tape 70mg' and 'KATRELP® Tape 35mg'.
Capital amount reduced to 100 million yen.
Approval obtained for methadone hydrochloride tablets; sales commenced the following year.
Approval obtained and sales commenced for the jointly developed fentanyl citrate buccal tablets with Daipon Pharmaceutical Co., Ltd.
Approval obtained for oxycodone hydrochloride extended-release capsules; sales commenced the following year.
The company's own pharmaceutical sales department was established; sales activities commenced after acquiring the sales rights for KATRELP, INTAVAN, and DRENIZON from Dai Nippon Sumitomo Pharma.
Completion of Factory 9 (tape formulation factory).
Tokyo office relocated to the Ogura Building in Kojimachi, Nihonbashi.
Established the East Japan Logistics Center in Kuki City, Saitama Prefecture.
Received the Order of the Rising Sun, Gold Rays with Rosette.
Approval obtained and sales commenced for 'RUPAFIN® Tablet 10mg'.
Completion of Factory 10 (ointment and cream manufacturing).
Celebrated 170th anniversary of founding and 100th anniversary of company establishment.
Made Selen Pharma Co., Ltd. a subsidiary.
Established the West Japan Logistics Center in Osaka City.
Selected for the Ministry of Economy, Trade and Industry's 'Top 100 Global Niche Companies 2020' list.
Certified as 'Euroboshi' under the Act on Promotion of Women's Participation in the Workplace.
Approval obtained for Japan's first transdermal rivastigmine formulation 'ALIDONE® Patch 27.5mg / ALIDONE® Patch 55mg'; sales commenced the following year.
Certified as 'Kurumin' under the Next-Generation Talent Development Support Promotion Act.
The website, which had been temporarily suspended for system maintenance, has resumed operations following the completion of security measures and various checks. We sincerely apologize for the inconvenience and trouble caused by the prolonged suspension.
Teikoku Seiyaku Co., Ltd. published information on the stable supply of prescription medicines. Forms 1–4, updated on April 10, provide details on its stable supply framework, contingency capacity, and supply plans and performance.